Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan
Authors
- Taito Esaki
- Taroh Satoh
- Kentaro Yamazaki
- Hisato Kawakami (ORCID: https://orcid.org/0000-0002-3280-4850)
- Cathy Eng (ORCID: https://orcid.org/0000-0003-2335-0612)
- Yu Sunakawa (ORCID: https://orcid.org/0000-0002-0163-7543)
- Atsuo Takashima
- Rajash Pallai
- Daisuke Kotani (ORCID: https://orcid.org/0000-0002-4196-555X)
- Toshiki Masuishi (ORCID: https://orcid.org/0000-0002-7521-1596)
- Shivani Nanda (ORCID: https://orcid.org/0000-0001-6358-2392)
- Takayuki Yoshino (ORCID: https://orcid.org/0000-0002-0489-4756)
- Marek Kania
- William R. Schelman
- Stacey M. Ukrainskyj
- Zhao Yang
- Yoshito Komatsu (ORCID: https://orcid.org/0000-0001-5448-6403)
- Tomohiro Nishina
Institutions
- St. Marianna University School of Medicine (JP)
- Vanderbilt University (US)
- Tohoku University (JP)
- Shizuoka Cancer Center (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Aichi Cancer Center (JP)
- Shikoku Cancer Center (JP)
- Hokkaido University Hospital (JP)
- National Cancer Center Hospital East (JP)
- Vanderbilt-Ingram Cancer Center
- Kindai University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1007/s10147-025-02852-9
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Takeda Pharmaceuticals U.S.A.